For biotechs in the industry’s handful of hot areas, it’s a seller’s market
A radiopharma company purchased for more than three times the price of its IPO from a few months earlier. Neuroscience companies driving up their offers by billions of dollars. Immunology assets going for hefty premiums.
Sellers have all the leverage right now, at least for the handful of companies in radiopharmaceuticals, neuroscience and inflammation, with assets that will try to fill a desperate need in a revenue-hungry Big Pharma industry.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.